VIM and breast carcinoma: Two of the 3 LAR models were KRT5 and KRT17 negative at the protein level, Vimentin was highly expressed in 2 out of 3 metaplastic breast cancer, which also showed loss of E-cadherin expression (Supplementary Figure S5).